Haemonetics Co. (NYSE:HAE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Haemonetics Co. (NYSE:HAE) has been assigned a consensus rating of “Moderate Buy” from the four analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $108.67.

A number of brokerages recently issued reports on HAE. Needham & Company LLC restated a “hold” rating on shares of Haemonetics in a report on Friday, May 10th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. JMP Securities raised their price target on Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research report on Friday, May 10th. Finally, Barrington Research raised their target price on shares of Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a report on Friday, May 10th.

Insider Buying and Selling at Haemonetics

In other news, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the transaction, the insider now owns 15,608 shares of the company’s stock, valued at approximately $1,498,992.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Stewart W. Strong sold 733 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total value of $70,397.32. Following the completion of the transaction, the insider now owns 15,608 shares of the company’s stock, valued at approximately $1,498,992.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Stewart W. Strong sold 8,857 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $87.53, for a total value of $775,253.21. Following the sale, the insider now owns 18,196 shares in the company, valued at approximately $1,592,695.88. The disclosure for this sale can be found here. Insiders have sold a total of 27,380 shares of company stock valued at $2,445,816 in the last ninety days. 1.79% of the stock is currently owned by company insiders.

Institutional Trading of Haemonetics

Several institutional investors have recently added to or reduced their stakes in HAE. TFO Wealth Partners LLC increased its holdings in Haemonetics by 29,450.0% in the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 589 shares in the last quarter. Group One Trading L.P. acquired a new position in shares of Haemonetics during the 3rd quarter valued at $55,000. Covestor Ltd lifted its position in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after acquiring an additional 438 shares during the period. EntryPoint Capital LLC bought a new position in Haemonetics during the first quarter worth $86,000. Finally, Parkside Financial Bank & Trust increased its stake in Haemonetics by 17.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after purchasing an additional 156 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $85.81 on Tuesday. The firm has a market cap of $4.36 billion, a P/E ratio of 37.47, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.50 and a current ratio of 2.56. Haemonetics has a twelve month low of $70.74 and a twelve month high of $97.97. The firm’s 50-day simple moving average is $88.93 and its 200-day simple moving average is $83.51.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to analyst estimates of $329.53 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The business’s revenue was up 12.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. As a group, research analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.